Peak Brand Sales for Lipitor
Lipitor (atorvastatin), made by Pfizer, hit peak annual sales of $12.9 billion in 2006, making it the world's top-selling drug before generic entry.[1]
Generic Entry Timeline
Lipitor's main U.S. patent expired November 30, 2011. Ranbaxy launched the first authorized generic that day, followed by Watson (now Teva) and others. Brand sales dropped 85% in the first full quarter of 2012.[1][2]
Sales Comparison Post-Generic Launch
| Year | Brand Lipitor Sales (Pfizer, $B) | Generic Atorvastatin Sales (Total U.S., $B) |
|------|---------------------------------|--------------------------------------------|
| 2011 | 5.5 (pre-full expiry) | ~0.4 (late-year entry) |
| 2012 | 1.3 | 7.5 |
| 2013 | 0.5 | 10.2 |
| 2014 | 0.2 | 11.5 |
Generics captured over 90% market share within months, with total atorvastatin sales (brand + generic) stabilizing around $12 billion annually by 2014—matching Lipitor's peak but at 80-90% lower prices.[1][3]
Price Impact on Sales Volume
Brand Lipitor pills cost $4-5 each pre-generic; generics launched at $0.40 per pill, driving volume up 20-30% as more patients started or switched therapy. U.S. payers saved $90 billion on statins from 2012-2020, mostly from Lipitor generics.[2][4]
Who Makes Generic Lipitor
Teva, Mylan (Viatris), Accord, and Dr. Reddy's lead U.S. generic sales. No active Lipitor patents block generics today.5
[1]: https://www.drugs.com/availability/generic-lipitor.html
[2]: FDA Orange Book and IMS Health data via FiercePharma
[3]: Pfizer annual reports 2011-2014
[4]: USC Schaeffer Center study on statin savings